Safety concerns about di-(2-ethylhexyl)phthalate (DEHP), a plasticizer and a probable endocrine disruptor, have attracted considerable public attention, but there are few studies about long-term exposure to DEHP. DEHP toxicity is thought to involve peroxisome proliferator-activated receptor ␣ (PPAR␣), but this contention remains controversial. For investigation of the long-term toxicity of DEHP and determination of whether PPAR␣ mediates toxicity, wild-type and PPAR␣-null mice were fed a diet that contained 0.05 or 0.01% DEHP for 22 mo. PPAR␣-null mice that were exposed to DEHP exhibited prominent immune complex glomerulonephritis, most likely related to elevated glomerular oxidative stress. Elevated NADPH oxidase, low antioxidant enzymes, and absence of the PPAR␣-dependent anti-inflammatory effects that normally antagonize the NFB signaling pathway accompanied the glomerulonephritis in PPAR␣-null mice. The results reported here indicate that PPAR␣ protects against the nephrotoxic effects of long-term exposure to DEHP. 
D i-(2-ethylhexyl)phthalate (DEHP)
, a probable endocrine disruptor, is used widely as a plasticizer for production of many types of polyvinyl chloride (PVC) consumer products. DEHP provides PVC items with the desired mechanical properties, including flexibility and strength. The presence of DEHP in the environment has been confirmed, as has product-related human exposure to DEHP; recent safety assessments of DEHP thereby have attracted much public interest (1) . DEHP continually enters the human body via food, water, and the atmosphere. Moreover, substantial human exposure to DEHP occurs via PVC-containing medical devices that are used in intravenous therapy, enteral and parenteral nutrition support, blood transfusion, hemodialysis, cardiopulmonary bypass, and extracorporeal membrane oxygenation (2) . Maximal medical exposure has been estimated to be near the US no-observed-adverse-effect level (3.7 to 14 mg/kg body wt per d). Many previous experimental animal studies yielded no obvious evidence of DEHP toxicities at these low exposure levels, but periods of exposure in the studies generally were brief. Long-term exposure to DEHP is important for safety assessment of real-world toxicity.
Past experimental animal studies using short-term exposure to high-dosage DEHP have demonstrated hepatotoxicity, testicular toxicity, renal toxicity, developmental disturbance, reproductive toxicity, and teratogenicity (3) (4) (5) . The peroxisome proliferator-activated receptor ␣ (PPAR␣), a member of the steroid/nuclear receptor superfamily of ligand-dependent transcription factors, has been implicated as a causative factor in these toxicities (6) . PPAR␣ is expressed abundantly in the rodent liver, testis, kidney, heart, digestive tract, and retina (7) and participates in diverse physiologic functions, including maintenance of lipid and glucose homeostasis (8 -11) , regulation of cell proliferation (12) , and modulation of inflammatory responses (13) . In humans, some ligands for this receptor, termed peroxisome proliferators, are used clinically as hypolipidemic agents, offering great benefits. However, ligand-related toxicities, such as hepatocarcinogenesis, have been observed in rodents (6) . Recent studies have established that human liver contains considerably lower levels of PPAR␣ than rodents, and this difference is thought to account for the species differences in effects of peroxisome proliferators (6) . DEHP, a peroxisome proliferator, was reported to cause primarily PPAR␣-dependent toxicity in rodents but is considered to be relatively safe in humans. However, some studies have associated DEHP with PPAR␣-independent renal and testicular toxicities (14, 15) ; accordingly, the mechanisms of DEHP toxicity as well as the reliability of DEHP safety assessments that have been conducted to date remain controversial.
Our study was designed to accomplish two goals: To determine whether dietary exposure to DEHP (0.01 or 0.05%) for 22 mo induces toxicity and to establish the relationship between PPAR␣ and DEHP-induced toxicity by comparing effects that were obtained between wild-type and PPAR␣-null mice. Longterm dietary exposure to DEHP induced glomerulonephritis in PPAR␣-null mice.
Materials and Methods

Animals and DEHP Treatment
PPAR␣-null and wild-type mice were on a SV/129 genetic background, as described elsewhere (16) . These mice were maintained in a facility that was free of specific pathogens according to Shinshu University and National Institutes of Health animal care guidelines and Accreditation of Laboratory Animal Care guidelines. The mice were housed in a temperature-and lightcontrolled environment (25°C; 12-h light/dark cycle) and maintained on stock rodent diet and tap water ad libitum until reaching 12 wk of age. Twelve-weekold male wild-type and PPAR␣-null mice (body weight for both 25 to 30 g) were fed their regular diet or a DEHP-containing diet (0.01 or 0.05%) for 22 mo. The beginning and ending sizes of each group were as follows: n ϭ 25 and 24 (one mouse died) for the control wild-type group; n ϭ 25 and 23 (two mice died) for the 0.01% DEHP wild-type group; n ϭ 21 and 20 (one mouse died) for the 0.05% DEHP wild-type group; n ϭ 26 and 25 (one mouse died) for the control PPAR␣-null group; n ϭ 28 and 25 (three mice died) for the 0.01% DEHP PPAR␣-null group; and n ϭ 34 and 31 (three mice died) for the 0.05% DEHP PPAR␣-null group. The clinical parameters of each group of mice were checked at 0, 6, 12, and 22 mo during the experimental period. Systolic BP was measured by a programmed sphygmomanometer (BP-98A; Softron Corp., Tokyo, Japan) using a tail-cuff method. Urine protein was measured as described previously (10) . Serum urea nitrogen and creatinine were determined by a clinical analyzer (JCA-BM2250; JEOL, Tokyo, Japan). All of the mice that had survived the 22-mo of experimental period were killed after finishing DEHP treatment. One PPAR␣-null mouse that was exposed to 0.05% DEHP exhibited marked hydronephrosis and therefore was not used in the histopathologic and biochemical analyses. The other mice showed no obvious abnormal macroscopic features, and the kidneys from these mice were used in the following analyses.
Histopathologic Analyses
Tissues from kidneys in each group of mice were fixed in 4% paraformaldehyde; embedded in paraffin; sectioned; and stained with hematoxylin and eosin, periodic acid-Schiff, or periodic acid-methenamine-silver for histopathologic examination using light microscopy. For semiquantitative histologic analyses, more than 20 glomeruli from each kidney section were examined. Degrees of cell proliferation and mesangial expansion were estimated using a scale that ranged from 0 to 3 (0, normal; 1, mild; 2, moderate; 3, severe). Indices were calculated using the following formula: Index ϭ (n 0 ϫ 0) ϩ (n 1 ϫ 1) ϩ (n 2 ϫ 2) ϩ (n 3 ϫ 3)/͚ n (͚ n Ͼ 20). These histopathologic analyses were performed in a blinded manner by two observers who were unaware of the study protocol. Cryosections for immunofluorescent analyses were stained using FITC-labeled anti-mouse C3, IgG, IgA, or IgM antibodies (ICN Pharmaceuticals, Aurora, OH). Paraffin sections were deparaffinized and stained using an indirect immunoperoxidase technique. A primary mAb to a mouse macrophage marker, F4/80 antigen, was purchased from BMA Biomedicals (Augst, Switzerland). Polyclonal primary antibodies to two oxidative stress markers, 4-hydroxynonenal (4-HNE) and 8-hydroxy-2Ј-deoxyguanosine (8-OHdG), respectively, were purchased from Alexis Corp. (Lausen, Switzerland) and Chemicon International (Temecula, CA). Tissues to be used for electron microscopy were fixed immediately in 2.5% glutaraldehyde, osmicated, dehydrated in increasing graded ethanol concentrations, and embedded in Epon resin. Ultrathin sections were double stained with uranyl acetate and lead citrate and examined with a JEM 1200EX II electron microscope (JEOL, Tokyo, Japan).
Immunoblot Analyses
For immunoblot analyses, glomeruli were isolated from all kidneys in each group of mice, using a previously described sieving method (17) . Glomerular extracts were subjected to 9 to 15% SDS-PAGE and then transferred to nitrocellulose membranes. These membranes were incubated with primary antibody, followed by incubation with alkaline phosphatase-conjugated secondary antibody. Polyclonal primary antibodies to catalase were prepared using purified catalase (18) . Primary antibodies to ␣-smooth muscle actin (␣-SMA) and 4-HNE were purchased from DakoCytomation (Glostrup, Denmark) and Alexis Corp, respectively. Other primary antibodies, against proliferating cell nuclear antigen, TGF␤1, Nox4, p47phox, Cu,Zn-superoxide dismutase (SOD), Mn-SOD, and glutathione peroxidase, were obtained from Santa Cruz Biotechnology (Santa Cruz, CA).
Analyses of mRNA
Analyses of mRNA were performed using a real-time PCR. One microgram of total RNA was extracted from the isolated glomeruli of each group and reverse-transcribed using oligo(dT) primers and Superscript reverse transcriptase (Invitrogen, Carlsbad, CA). The cDNA were quantified with an ABI PRISM 7700 sequence detection system (Applied Biosystems, Foster City, CA), using specific primers and SYBR Green double-stranded DNA (dsDNA) binding dye I. Specific primers were designed as follows: 5Ј-CCTCAGGGTACCACTACGGAGT-3Ј and 5Ј-GCCGAATAGTTCGCCGAA-3Ј for PPAR␣ (GenBank accession no. NM_011144); 5Ј-TTCCACTATGGAGTTCATGCTTGT-3Ј and 5Ј-TCCG-GCAGTTAAGATCACACCTA-3Ј for PPAR␥ (NM_011146); 5Ј-CACCT-GCAAGACCATCGACAT-3Ј and 5Ј-TGGCGAGCCTTAGTTTGGA-3Ј for TGF␤1 (NM_011577); 5Ј-GCCCCGCACAGCCATGTTTCAG-3Ј and 5Ј-CATGGAGTCCAGGCCGCTGTCGTG-3Ј for IB␣ (U36277); 5Ј-TGAC-CCCCAAGGCTCAAATATG-3Ј and 5Ј-ACCCAGGTCCTCGCTTATGAT-3Ј for cyclooxygenase2 (NM_011198); 5Ј-TCCGGACTTTCGATCTTCCA-3Ј and 5Ј-GAGCTTCAGAGGCAGGAAACA-3Ј for intercellular adhesion molecule 1 (M31585), 5Ј-CAGCCGATGGGTTGTACCTT-3Ј and 5Ј-GT-GGGTGAGGAGCACGTAGTC-3Ј for TNF␣ (NM_013693); 5Ј-CGTCCT-GACAATGCAGACCTT-3Ј and 5Ј-CCCCATGAAACGCATGAACT-3Ј for TNF receptor 1 (TNR1) (M60468). Glyceraldehyde-3-phosphate dehydrogenase was used as the internal control for PCR amplification.
Measurement of Serum Mono(2-Ethylhexyl)Phthalate Concentration
Serum mono(2-ethylhexyl)phthalate (MEHP) concentration was measured as described previously (19) . Briefly, MEHP was extracted from serum samples with ethyl acetate. N-Methyl-N-(tert-butyl-dimethylsilyl)trifluoroacetamide (GL Sciences, Tokyo, Japan) was added to the MEHP extracts and left at room temperature for 60 min. The MEHP tert-buthyl-dimethylsilyl derivative was analyzed by gas chromatography with mass-selective detection (6890 N, 5973 N; Agilent Technologies, Santa Clara, CA). Serum samples of hemodialysis (HD) patients and healthy volunteers were collected in July 2006 with written informed consent. This study was conducted in accordance with the Declaration of Helsinki. Signed informed consent to participate in the study was obtained from all of the patients, and the study protocols were approved by the Medical Ethics Committee of the Shinshu University School of Medicine.
Measurements of Anti-dsDNA Antibody and 50% Hemolytic Complement Activity
The titer of serum anti-dsDNA antibody was determined by ELISA as shown previously (20) . The standard 50% hemolytic complement activity (CH50) was measured as described previously (21) .
Statistical Analyses
Analysis of significant differences with respect to interactive effects of two factors (PPAR␣ gene status and DEHP treatment) was performed using a two-way ANOVA. P Ͻ 0.05 was used as the measure of significance.
Results
DEHP Exposure Levels and Serum MEHP Concentrations
Food consumption during the experimental period was uninterrupted and similar in all groups (3.1 Ϯ 0.7 g/d per mouse). Mean daily ingestion of DEHP approximated the maximal medical exposure in humans (8 to 11 mg/kg body wt per d for the 0.01% DEHP groups of wild-type and PPAR␣-null mice; 42 to 55 mg/kg body wt per d for the 0.05% DEHP groups of the two genotypes; Ͻ22.6 mg/kg body wt per d for patients undergoing therapy using PVC-containing medical devices [2] ). Because most ingested DEHP is hydrolyzed efficiently by lipases to MEHP, a major DEHP metabolite whose toxicity is much more intensive than that of DEHP (2), the serum MEHP concentration in each group of mice at 22 mo was measured. The concentration increased in a DEHP dosage-dependent manner in DEHP-exposed mice of both genotypes, and there was no difference between the genotypes statistically (0.047 Ϯ 0.014 and 0.041 Ϯ 0.007 g/ml for the control groups of wildtype [n ϭ 24] and PPAR␣-null mice [n ϭ 25], respectively; 0.370 Ϯ 0.097 and 0.429 Ϯ 0.140 g/ml for the 0.01% DEHP groups of wild-type [n ϭ 23] and PPAR␣-null mice [n ϭ 25], respectively; 1.404 Ϯ 0.371 and 1.737 Ϯ 0.689 g/ml for the 0.05% DEHP groups of wild-type [n ϭ 20] and PPAR␣-null mice [n ϭ 30], respectively). These findings suggest that the DEHP exposure levels that were chosen in this study well influence the serum concentrations of the major active metabolite, MEHP. Serum concentrations of MEHP in HD patients, who are exposed frequently to DEHP through HD sessions, were unexpectedly lower (0.056 Ϯ 0.018 g/ml [0.016 to 0.110 g/ml] for the HD patients after the HD sessions [n ϭ 109]; 0.014 Ϯ 0.003 g/ml for the healthy volunteers [n ϭ 16]) than those in DEHP-exposed mice. Therefore, these findings indicate that serum MEHP concentrations probably are influenced by a species difference in DEHP metabolic efficiency.
Systemic Effects of Long-Term Dietary Exposure to DEHP
The systemic effects in all groups of mice were followed up throughout the experimental period. The levels of systolic BP, daily urinary protein excretion, serum urea nitrogen, and serum creatinine did not differ among the groups until 6 mo. Systolic BP and daily urinary protein excretion in DEHP-exposed PPAR␣-null mice increased in time-dependent and DEHP dosage-dependent manners after 6 mo ( Figure 1, A and   B ). Outstanding increases of urine protein excretion in 0.01 and 0.05% DEHP-exposed PPAR␣-null mice were observed at both 12 and 22 mo, but the development of hypertension in 0.01% DEHP-exposed PPAR␣-null mice was obscure ( Figure 1, A and  B) . Therefore, hypertension may have begun to develop after proteinuria. At 22 mo, obvious increases in serum urea nitrogen and serum creatinine in DEHP-exposed PPAR␣-null mice were observed in a DEHP dosage-dependent manner (Figure 1, C  and D) . Systolic BP and daily urinary protein excretion in exposed wild-type mice slightly increased at 22 mo, but serum urea nitrogen and serum creatinine did not change at any time during the experimental period. These data suggest DEHPdependent renal dysfunction especially in exposed PPAR␣-null mice.
In all groups, body weight, kidney weight, and testicular weight were not different among the groups; however, liver weight in exposed wild-type mice at 22 mo decreased in a dosage-dependent manner (liver weight/body weight 4.28 Ϯ 0.64% for the control wild-type group, 3.98 Ϯ 0.45% for the 0.01% DEHP wild-type group, and 3.92 Ϯ 0.26% for the 0.05% DEHP wild-type group). Because this effect was not observed in PPAR␣-null mice, the decrease in liver weight most likely reflected PPAR␣-dependent long-term hepatotoxicity. Because symptoms that were related to renal dysfunction were prominent, we focused on renal toxicity in the subsequent analyses.
DEHP Induces Immune-Complex Glomerulonephritis
The cause of renal dysfunction that was observed in these mice was examined by histopathologic analyses. Light microscopy using periodic acid-methenamine-silver staining demonstrated outstanding glomerular lesions with cellular proliferation and mesangial expansion in all of DEHP-exposed PPAR␣-null mice at 22 mo (Figure 2A ). Cell proliferation and mesangial expansion in exposed PPAR␣-null mice increased in a dosagedependent manner (Figure 2 , B and C). Approximately 25% of PPAR␣-null mice that were exposed to 0.05% DEHP showed severe inflammatory findings such as mesangiolysis, mesangial edema, crescent formation, and macrophage infiltration ( Figure  2, D and E) . In contrast, only mild glomerular lesions were seen in DEHP-exposed wild-type mice. These findings indicate that long-term exposure to DEHP induces DEHP-dependent glomerulonephritis in PPAR␣-null mice.
Light microscopy also demonstrated focal tubulointerstitial lesions with tubular atrophy and inflammatory cell infiltration in DEHP-exposed PPAR␣-null mice. These tubulointerstitial lesions were localized around the sclerotic glomerular lesions (Figure 3) . The lesions, reported in earlier studies, such as cystic tubular dilation, tubular necrosis, tubular pigmentation, and papillary mineralization (14, 22) , were scarcely detected here. These findings suggest that secondary tubulointerstitial lesions developed after glomerular damages occurred.
For further characterization of DEHP-induced glomerulonephritis in PPAR␣-null mice, immunofluorescent and electron microscopic analyses were performed. Immunofluorescence staining demonstrated C3, IgG, IgA, and IgM deposits along peripheral glomerular capillaries in DEHP-exposed PPAR␣-null mice at 22 mo ( Figure 4A ). Electron microscopic analysis revealed massive subepithelial electron-dense deposits and diffuse foot process effacement in DEHP-exposed PPAR␣-null mice ( Figure 4B) . A small number of mesangial and subendothelial deposits also were detected. In age-matched unexposed PPAR␣-null mice, immunofluorescence staining indicated only a few deposits in glomeruli, and electron microscopic analysis showed no abnormal changes in podocytes. These findings suggest that this glomerulonephritis involves immune mechanisms that are affected by DEHP treatment. In each mouse group, there was no appearance of anti-dsDNA antibody and no decrease in CH50. Therefore, DEHP's affecting glomerular immune-complex deposition seemed to act not systemically but renal specifically.
For further characterization of the glomerular lesions, known mediators of mesangial cell proliferation and fibrosis, specifically, ␣-SMA, proliferating cell nuclear antigen, and TGF␤1, were measured by immunoblotting. Expression of these proteins was increased markedly in PPAR␣-null mice at 22 mo in a DEHP dosage-dependent manner but increased only slightly in wild-type mice ( Figure 4C ). These findings are in agreement with the pathologic findings.
DEHP Elevates Oxidative Stress in Glomeruli
Because some studies have suggested that DEHP-induced elevation of oxidative stress contributes to hepatotoxicity and testicular toxicity (23) (24) (25) , the influence of oxidative stress in DEHP-induced glomerulonephritis was examined. Immunoblot analysis showed that total amounts of 4-HNE-modified proteins, a lipid peroxidation marker, were increased markedly and dosage dependently in glomeruli of DEHP-exposed PPAR␣-null mice at 22 mo but increased only mildly in exposed wild-type mice ( Figure 5A ). By immunohistochemical analyses, the 4-HNE-modified proteins were detected in large numbers of podocytes in the glomeruli of DEHP-exposed PPAR␣-null mice at 22 mo ( Figure 5B ). These podocytes also contained 8-OHdG, an oxidative DNA damage marker ( Figure 5C ). These oxidative stress markers also showed slight positivity in parietal epithelial cells and proximal tubules of DEHP-exposed PPAR␣-null mice. Next, glomerular protein expression levels of two superoxide-generating NADPH oxidase subunits, Nox4 and p47phox, were examined. These proteins were increased markedly and dosage dependently in DEHP-exposed PPAR␣-null mice at 22 mo; these increases were present but reduced Figure 1 . Effects of a diet that included di-(2-ethylhexyl)phthalate (DEHP; 0.01 or 0.05%) during 22 mo in wild-type (WT) and peroxisome proliferator-activated receptor ␣ (PPAR␣)-null (KO) mice. Systolic BP (A), daily urinary protein excretion (B), serum urea nitrogen (C), and serum creatinine (D) were measured. F, control WT group (n ϭ 24); f, 0.01% DEHP WT group (n ϭ 23); OE, 0.05% DEHP WT group (n ϭ 20); E, control KO group (n ϭ 25); Ⅺ, 0.01% DEHP KO group (n ϭ 25); ‚, 0.05% DEHP KO group (n ϭ 30). Data are means Ϯ SD. *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001, significantly different from the respective control group; # P Ͻ 0.05, ## P Ͻ 0.01, ### P Ͻ 0.001, significant differences between WT and KO mice.
considerably in wild-type mice ( Figure 6A ). The findings suggest an increase in the generation of reactive oxygen species (ROS) in glomeruli. To this end, glomerular antioxidant protein expression was measured in each group at 22 mo. Constitutive expression of catalase, Cu,Zn-SOD, and Mn-SOD was lower in unexposed PPAR␣-null mice than in wild-type mice; DEHP exposure further reduced glomerular expression of these proteins in PPAR␣-null mice ( Figure 6B ). Glutathione peroxidase-1 expression remained constant in all groups. These findings suggest that DEHP exposure increases oxidative stress in glomeruli, especially in podocytes, and this effect is intensified greatly in PPAR␣-null mice, 
PPAR␣ Exerts Antinephritic Effects
For investigation of the mechanism underlying development of glomerulonephritis in DEHP-exposed PPAR␣-null mice, expressions of mRNA encoding mediators of inflammation and fibrosis were examined, using glomerular samples at 22 mo. Because PPAR␣ and PPAR␥ show anti-inflammatory effects in many tissues (13) , the mRNA that encodes these transcription factors were measured using real-time PCR. As expected, glomerular expression of PPAR␣ in PPAR␣-null mice remained almost undetectable throughout the experiment. Conversely, constitutive glomerular expression of PPAR␣ in wild-type mice was high and increased in a DEHP dosage-dependent manner ( Figure 7A ). Constitutive glomerular expression of mRNA that encodes PPAR␥, which was much less than that of PPAR␣ in wild-type mice, did not differ between the genotypes and was decreased slightly by DEHP exposure in mice of both genotypes ( Figure 7B ). These findings suggest that PPAR␥ is not important in development of DEHP-induced glomerulonephritis. Because it was reported recently that hepatic expression of fibrogenic growth factor mRNA was influenced by PPAR␣ expression (26), TGF␤1 mRNA was measured. Expression increased markedly in DEHP-exposed PPAR␣-null mice in a dosage-dependent manner, whereas the increases were only marginal in wild-type mice ( Figure 7C ). This mRNA expression pattern was consistent with the changes that were observed at the protein level ( Figure 4C ). Because PPAR␣ is known to exert anti-inflammatory effects by inducing expression of IB␣, which antagonizes NFB signaling (27) , the expression of IB␣ was measured. This mRNA was found to remain constant in exposed PPAR␣-null mice but increased dosage dependently in exposed wild-type mice ( Figure 7D ). These results were compatible with the observed pattern of PPAR␣ mRNA expression. Next, the expression of mRNA that encode three proinflammatory mediators-cyclooxygenase 2, intercellular adhesion molecule 1, and TNF␣, known as target molecules of the NFB signaling pathway-were determined. Expression of the proinflammatory genes was increased considerably and dosage dependently in DEHP-exposed PPAR␣-null mice but was increased only mildly in exposed wild-type mice (Figure 7 , E through G). In addition, the expression of TNR1 mRNA was measured to evaluate the sensitivity to the inflammatory response in PPAR␣-null mice. Surprising, constitutive expression of TNR1 was markedly higher in PPAR␣-null mice than in wild-type mice; this enhanced expression remained constant irrespective of exposure to DEHP ( Figure  7H ). These results suggest that PPAR␣ exerts antinephritic effects by antagonizing the NFB signaling pathway, preventing fibrosis, and lowering inflammatory sensitivity.
Discussion
Our study demonstrated that long-term dietary exposure to DEHP induced hypertension, proteinuria, renal dysfunction, and prominent immune-complex glomerulonephritis in PPAR␣-null mice. Development of glomerulonephritis seemed to be related to elevations in glomerular oxidative stress that resulted from exposure to DEHP. Glomerulonephritis was exaggerated by an increased NADPH oxidase and low antioxidant response and absence of PPAR␣-dependent anti-inflammatory effects, thus indicating the protection of DEHP nephrotoxicity by PPAR␣. DEHP-induced glomerulonephritis was found for the first time in this study. The known DEHP tubulointerstitial toxicities, reported in previous studies using high dosages of DEHP in short-term periods (14, 22) , did not appear in our study. The discrepancy in renal pathology between the earlier studies and this study probably is derived from differences in study design. It has been established that old laboratory mice exhibit the development of spontaneous subclinical immune-complex glomerulonephritis (28) . In this study, a 22-mo experimental period was required for the appearance of outstanding glomerulonephritis in almost all DEHP-exposed PPAR␣-null mice. Therefore, the consideration of aging's effects on PPAR␣-null mice would be important. Indeed, a few glomerular immunecomplex depositions were detected in unexposed PPAR␣-null mice at 22 mo. Moreover, urine protein excretion, glomerular protein expression of ␣-SMA, and mRNA contents of inflammatory mediators were slightly higher in these mice than in unexposed, old, wild-type mice. These findings indicate that old PPAR␣-null mice per se have some degree of spontaneous glomerular damages. However, these changes were very limited, as reported in an earlier study that showed spontaneous aging changes in PPAR␣-null mice (29) . Therefore, the spontaneous aging effects probably contributed slightly to the development of glomerulonephritis in the exposed PPAR␣-null mice.
Oxidative stress is associated with pathophysiologic events in a variety of diseases. In particular, 4-HNE, a major end product of lipid peroxidation that exhibits a variety of cytotoxic effects in many types of cells (30) , contributes to the pathogenesis of glomerulonephritis, causing injury to cell membranes of podocytes and to glomerular basement membrane (31, 32) . Indeed, in this study, 4-HNE and 8-OHdG were detected mainly in podocytes of DEHP-exposed PPAR␣-null mice, suggesting that these podocytes experienced very high levels of oxidative stress. Accordingly, several pathogenic scenarios of DEHP toxicity can be postulated: (1) Lipid peroxidation that is elevated by DEHP exposure causes podocyte injury, followed by foot process effacement that entraps circulating immune complexes in the subepithelial space, leading in turn to the development of immune complex glomerulonephritis and/or (2) lipid peroxidation damages the glomerular basement membrane or cell membranes of podocytes to introduce novel antigens, followed by in situ immune complex formation and finally development of glomerulonephritis. Because staining for 4-HNE was slightly positive in the proximal tubules of DEHP-exposed PPAR␣-null mice, another pathogenic sequence, resembling events in Heymann nephritis and involving exposure of tubular antigens, may take place. Earlier studies reported that either NF-E2-related factor 2 (Nrf2) or heme-oxygenase 1-deficient mice, which were very sensitive to oxidative stress, also developed immune complex glomerulonephritis similar to our case morphologically (20, 33) . The development of glomerulonephritis in old Nrf2-deficient mice was practically female specific and was mediated by systemic immune disturbances, such as the appearance of anti-dsDNA antibody and the decrease of complement factors that was derived from severe oxidative stress (20) . In our study using male mice, DEHP toxicities that affected glomerular immune deposits seemed to be renal specific, suggesting the presence of a nephrotoxic mechanism that is different from that in Nrf2-deficient mice. It remains unknown whether DEHP treatment causes systemic immune disturbances in PPAR␣-null female mice.
Our study revealed PPAR␣-independent effects of DEHP that resulted in enhanced activation of NADPH oxidase. To date, NADPH oxidase is the most thoroughly investigated ROS-generating system. Recent studies have implicated induction of NADPH oxidase via PPAR␣ as the main molecular source of PPAR␣ agonist-induced ROS (34) . Contrary to these reports, our data suggest that DEHP can induce increases in glomerular NADPH oxidase proteins without involvement of PPAR␣. A recent study using Kupffer cells also reported that DEHP increased production of ROS in a PPAR␣-independent manner via NADPH oxidase (35) . These results support the hypothesis that PPAR␣ is not involved in the increase in ROS Figure 6 . Changes in amounts of glomerular oxidative stress-related factors in DEHP-exposed WT and KO mice. (A and B) Immunoblot analyses of Nox4, p47phox, catalase, Cu,Zn-superoxide dismutase (Cu,Zn-SOD), Mn-SOD, and glutathione peroxidase (GPx-1). Twenty micrograms of glomerular lysate protein that was obtained from all kidneys in each group of mice at 22 mo of experiment was used. Blotting and densitometry were performed in triplicate. Data are means Ϯ SD. **P Ͻ 0.01, ***P Ͻ 0.001, significantly different from the respective control group; ## P Ͻ 0.01, ### P Ͻ 0.001, significant differences between WT (f) and KO (Ⅺ) mice.
that is caused by DEHP, an indicator of PPAR␣-independent toxicity of DEHP. Recently, a novel gp91phox homologue termed Nox4 was identified in nonphagocytic cells such as mesangial cells (36) , and this component was reported to correlate significantly with the content of ␣-SMA-positive cells (37) . The other NADPH oxidase components, p47phox, Figure 7 . Changes in glomerular mRNA expression in DEHP-exposed WT and KO mice. (A through H) Analyses of mRNA in isolated glomeruli that were obtained from all kidneys in each group of mice at 22 mo of experiment. PPAR␣ (A), PPAR␥ (B), TGF␤1 (C), IB␣ (D), cyclooxygenase 2 (COX2; E), intercellular adhesion molecule 1 (ICAM1) (F), TNF␣ (G), and TNF receptor 1 (TNR1; H). The mRNA were quantified by real-time PCR. Glyceraldehyde-3-phosphate dehydrogenase mRNA was used as an internal control. Data are means Ϯ SD of triplicate experiments. *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001, significantly different from the respective control group; # P Ͻ 0.05, ## P Ͻ 0.01, ### P Ͻ 0.001, significant differences between WT (f) and KO (Ⅺ) mice.
p22phox, and p67phox, also were reported to be induced by inflammatory stimulants in human mesangial cells (38) . Because DEHP-exposed PPAR␣-null mice exhibited obvious mesangial cell proliferation and glomerular ␣-SMA protein increase, probably reflecting mesangial cell activation that was caused by excessive inflammatory mediators, these marked phenotypic changes may result in the intense glomerular NADPH oxidase response in PPAR␣-null mice. Furthermore, our study revealed an interesting relationship between antioxidant activity and PPAR␣. It was noteworthy that constitutive expression of the antioxidant proteins such as catalase, Cu,Zn-SOD, and Mn-SOD was significantly low in PPAR␣-null mice and that these proteins showed decreases in response to DEHP exposure. This suggests that PPAR␣ plays an important antioxidative role in glomeruli by contributing to the constitutive regulation of these proteins. Supporting this interpretation, the promoter regions for catalase and Cu,Zn-SOD possess PPAR response elements (39, 40) . No study has investigated the presence of a potential PPAR response elements in Mn-SOD gene promoter, which was characterized by a GC-rich region that contained multiple specificity protein 1 (Sp1)-binding sites (41) . Several studies demonstrated that PPAR␣ could interact with the Sp1 multigene family proteins and interfere in Sp1-dependent gene transcription (42) . Therefore, PPAR␣ may maintain transcription of Mn-SOD gene via this mechanism.
Our study also indicates that PPAR␣ acts against DEHPinduced glomerulonephritis via transcriptional regulation of IB␣. Earlier studies established an influence of PPAR␣ in the NFB signaling pathway (13, 27) . However, the importance of PPAR␣ in glomerulonephritis has been insufficiently recognized, because glomerular PPAR␣ expression was reported to be low (43) . A very recent report demonstrated that a large amount of PPAR␣ existed in the nuclei of mesangial and epithelial cells in glomeruli (44) , which supports the antinephritic effects of PPAR␣ as revealed in our study. In addition to these effects, PPAR␣ may be involved in reducing glomerular sensitivity to inflammatory mediators, because TNR1 mRNA expression was constantly higher in PPAR␣-null mice. Expression of TNR1 was reported to be regulated by several types of cytokines, including TNF␣ (45); therefore, the development of inflammation in PPAR␣-null mice may result from the synergistic effect of cytokines. It was suggested that all three PPAR may be novel therapeutic targets for treating renal diseases (46) . Our findings may offer clues to develop renal PPAR-based disease therapies.
Taken together, our findings suggest that DEHP-induced glomerulonephritis develops if pathogenic effects of DEHP exceed the protective capacity of PPAR␣-dependent antinephritic effects. At present, DEHP-induced glomerulonephritis has been detected only in mice, not in humans. Moreover, our findings indicate the presence of a species difference in DEHP metabolic efficiency. Therefore, it would be difficult to evaluate our findings as a risk assessment for humans who are exposed continuously to DEHP. It remains to be determined whether the nephrotoxic effects of long-term exposure to DEHP can be reversed after withdrawal of the compound.
